There are some very big dogs in the cardiovascular device space and Abbott Laboratories is about to become one of the biggest in the yard. The Abbott Park, Ill.-based company made a bid to acquire St. Jude Medical Inc. for $25 billion plus the assumption of $5.7 billion in debt. The deal sets St. Jude shareholders up to get $46.75 in cash and 0.8708 shares of Abbott common stock, for a total consideration of roughly $85 a share. The price represents a 37 percent premium to St. Jude's closing price Wednesday. Read More
